

BACKGROUND

- Patient training for self-injectable medications varies greatly, with some receiving no or minimal in-clinic training and training resources
- In-clinic training shows variations in time, methods, and effectiveness
- **Remote Demonstration Kits (RDks)** with high-fidelity devices are an alternative for at-home self-injection practice
- Supplying RDks to patients via Healthcare Providers and Pharma HUB services has been considered, but logistics and awareness of services may prove challenging
- Specialty pharmacy, given its role in supplying self-injectable medications, is well-positioned to provide patient training and distribute RDks effectively



OBJECTIVE



- This exploratory pilot aimed to **investigate the impact of supplying self-injection RDks** (IFU, injection demonstration device and video) to patients via specialty pharmacy

METHODS

- Patients were randomized equally into two groups: Standard of Care (SoC) or SoC + RDk. The RDk was shipped on the same day as the first dose, and Patient Reported Outcome (PRO) data was collected at intervals, alongside patient refill data from the specialty pharmacy
- Inclusion Criteria: Prescribed one of three biologics (all with a 14-day dosing schedule) and naive to self-injection medication

Measure	Measure description
Script-to-Injection	✓ Patients reported 1 st self-injection
Adherence	✓ Patients claimed 1 st refill
Persistence	✓ Patients who were eligible for 3 dispenses

RESULTS




Persistence Impact (Preliminary Findings)

Group	Persistence Rate*
Control Group (SoC only)	82%
Treatment Group (SoC + RDk)	94%

* Patients discharged between refills due to co-pay and side effects are not included in the persistence calculation

RESULTS



CONCLUSIONS

- **Script-to-Injection Days**: Patients who received the RDk **took their first injection significantly faster (38%)** than those who received only standard of care
- **Short-term Adherence (PDC)**: Patients who received the RDk are **40% more likely to reach an acceptable 80% PDC** than those who only received standard of care
- **Persistence to therapy**: Early persistence data shows a **15% improvement in patients persisting to therapy**
- **Patient perceptions**: Patients who receive the RDk are **highly likely to use it for on their initial dose (88%) and highly likely to reuse the training kit (88%) for re-orientation during later doses**

Limitations:

- Small sample size warrants further study with larger sample
- Script-to-Injection Days were not assessed if the 1st injection date was not available via survey
- This pilot study's scope was limited to demonstrating short-term adherence impact due to its relatively brief duration